HansBiomed Corporation (KOSDAQ:042520)

South Korea · Delayed Price · Currency is KRW

18,110

-470 (-2.53%)

At close: Oct 22, 2026

Market Cap	258.27B -14.6%
Revenue (ttm)	124.81B +45.9%
Net Income	-19.66B
EPS	-1,433.17
Shares Out	14.26M
PE Ratio	n/a
Forward PE	11.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	213,769
Open	17,800
Previous Close	18,580
Day's Range	17,360 - 18,590
52-Week Range	15,300 - 57,800
Beta	2.02
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 18, 2026

About HansBiomed

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product tha... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1990

Employees 315

Stock Exchange KOSDAQ

Ticker Symbol 042520

Full Company Profile

Financial Performance

In fiscal year 2025, HansBiomed's revenue was 89.78 billion, an increase of 10.65% compared to the previous year's 81.14 billion. Losses were -31.34 billion, 333.9% more than in 2024.

Financial Statements